ABSTRACT
【Objective】 To investigate the psychological status of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and to analyze the effects of anxiety on the total National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) in patients in Ngari Prefecture of Tibet. 【Methods】 CP/CPPS patients treated during Oct.2019 and Oct.2021 were involved and divided into anxiety group and non-anxiety group. The non-anxiety group received routine drug treatment, while the anxiety group received drugs and psychological intervention. 【Results】 A total of 117 patients were involved, including 68 in the anxiety group and 49 in the non-anxiety group. There were no statistical differences between the two groups in terms of age, body mass index (BMI), marital status, smoking history, and education level (P>0.05). The total NIH-CPSI score in the anxiety group (18.53±3.47) was higher than that in non-anxiety group (15.67±3.33), which was mainly manifested by the increase of pain and decrease of quality of life scores. Further stratification of anxiety level revealed that quality of life score and total NIH-CPSI score increased as anxiety symptoms worsened. After drug treatment, pain and urination symptoms were improved in the non-anxiety group, but the quality of life score and total NIH-CPSI score did not change significantly. After psychological intervention, the anxiety group had lower total NIH-CPSI score and other scores. 【Conclusion】 It is not uncommon for CP/CPPS patients to have a comorbidity of anxiety. The increase in the total NIH-CPSI score is caused by the increase of pain score and decrease of quality of life score. Active psychological intervention can improve anxiety, urinary symptoms, pain symptoms and quality of life.
ABSTRACT
Objective: To investigate the clinical efficacy of Xueniaoan Capsule combined with levofloxacin in the treatment of chronic bacterial prostatitis. Methods: A total of 126 patients with chronic bacterial prostatitis were randomly divided into control group (n = 60) and observation group (n = 66). The control group was treated with levofloxacin hydrochloride tablets (0.6 g/d, po) and the observation group was treated with Xueniaoan Capsule (4.2 g/d, po) combined with levofloxacin hydrochloride tablets (0.6 g/d, po). Both groups were continuously treated for eight weeks. The clinical efficacy of the two groups was evaluated through the NIH-CPSI score, prostatic fluid bacterial culture negative conversion rate, and serological parameters. Results: After treatment, the clinical efficacy in the control and treatment groups were 66.67% and 89.39%, respectively, and there were statistical differences between two groups (P < 0.05); Statistical analysis showed that the pain symptom score (5.45 ± 1.12), urination symptom score (3.31 ± 0.70) and quality of life score (3.08 ± 0.55) of NIH-CPSI scale in the observation group were significantly lower than those of the control group (P < 0.05); The negative conversion rate of prostatic fluid bacterial culture was 71.67% in the control group and 92.42% in the observation group, and the difference between the two groups had statistical significance (P < 0.05); The serum levels of interleukin-6 (IL-6), interleukin-8 (IL-8), and high-sensitivity C-reactive protein (hs-CRP) in the two groups were significantly lower than those before treatment (P < 0.05), while the levels of inflammatory factors in the observation group were significantly lower than those in the control group (P < 0.05). Conclusion: Xueniaoan Capsule combined with levofloxacin is effective in the treatment of chronic bacterial prostatitis, and can effectively relieve the clinical symptoms, improve the rate of prostatic fluid bacterial clearance, and reduce the level of serum inflammatory factors, which has a certain clinical application value.